Corcept Therapeutics (CORT) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Corcept Therapeutics Announces Second Quarter 2015 Results and Provides Corporate Update
August 5, 2015 4:06 PM EDTMENLO PARK, CA -- (Marketwired) -- 08/05/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT)
Per-share net loss in the second quarter narrows to $0.02, from $0.07 in the same period last year Excluding non-cash expenses, non-GAAP net income for the second quarter is $369,000, compared to a non-GAAP net loss of $5.4 million in the second quarter of 2014 Second quarter revenue is $12.0 million, compared to $5.9 million in the second quarter of 2014, a 104 percent increase 2015 revenue guidance is revised to $49 - $53 million Patient dosing continues in the efficacy portion of the company's Phase 1/2 trial... More